Page last updated: 2024-08-21

quinazolines and Lung Diseases, Interstitial

quinazolines has been researched along with Lung Diseases, Interstitial in 112 studies

Research

Studies (112)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	49 (43.75)	29.6817
2010's	62 (55.36)	24.3611
2020's	1 (0.89)	2.80

Authors

Authors	Studies
Aul, R; Hill, M; Howlett, S; Pinato, DJ	1
Ito, T; Kajiguchi, T; Kamoshita, S; Kimura, T; Yagi, M	1
Kaneda, H; Koyama, A; Matsuoka, H; Nakagawa, K; Nishio, K; Sakai, K	1
Komada, F	1
Ahsmann, EJ; Eshuis, M; van Egmond, NH	1
Fujiwara, Y; Horinouchi, H; Kanda, S; Kubota, K; Nakamichi, S; Nokihara, H; Tamura, T; Yamamoto, N	1
Atagi, S; Fukuoka, M; Imai, M; Katakami, N; Kudoh, S; Matsui, S; Ogiwara, A; Ueda, M; Yoshioka, H	1
Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK	1
Akamatsu, H; Inoue, A; Kobayashi, K; Mitsudomi, T; Mori, K; Nakagawa, K; Nakanishi, Y; Nukiwa, T; Yamamoto, N	1
Ishiguro, H; Ishiguro, Y; Miyamoto, H	1
Liu, Z; Shi, L; Tang, J; Tong, L	1
Qi, WX; Shen, Z; Sun, YJ; Yao, Y	1
Arakawa, H; Fukuoka, M; Harada, R; Johkoh, T; Kudoh, S; Kusumoto, M; Sakai, F; Ueda, M	1
Akiyama, Y; Fujita, K; Hirose, T; Kusumoto, S; Nakashima, M; Sasaki, Y; Shirai, T; Sugiyama, T	1
Ando, M; Arakawa, H; Ebina, M; Fukuda, Y; Fukuoka, M; Gemma, A; Inoue, Y; Ishii, T; Johkoh, T; Kudoh, S; Kusumoto, M; Kuwano, K; Nakagawa, K; Ohe, Y; Sakai, F; Seki, A; Taniguchi, H; Yamazaki, N	1
Enoki, H; Katahira, K; Teraoka, A; Tsuchiya, Y; Yoshikawa, T	1
Bugés, C; Capdevila, L; Carcereny, E; Cardona, AF; Cros, S; Moran, T; Reguart, N; Rosell, R	1
Beom, SH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, JO; Lee, SH; Park, JH; Sim, SH	1
Abdel-Rahman, O; Elhalawani, H	1
Carreres-Prieto, M; Layos-Romero, L; López-Sisamón, D	1
Aprile, G; Cardellino, GG; Foltran, L; Macerelli, M; Mazzer, M	1
Imai, S; Koyama, S; Matsubara, K; Nakagawa, S; Nakagawa, T; Omura, T; Yano, I; Yonezawa, A	1
Chen, H; Han, R; He, Y; Huang, W; Li, K; Li, L; Lin, C; Lu, C; Sun, F; Wang, Y; Zhang, K	1
Aida, Y; Fujita, K; Hida, N; Hizawa, N; Morishima, Y; Nakazawa, K; Sekine, I; Shiozawa, T; Tsunoda, Y	1
Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA	1
Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S	2
Yamamoto, C; Yamamoto, D; Yamamoto, M	1
Khuri, FR; Roman, J	1
Fukuhara, T; Inoue, A; Kanehira, M; Kikuchi, T; Kuroki, Y; Maemondo, M; Nukiwa, T; Saijo, Y; Suzuki, T; Xin, H	1
Grünberg, K; Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF	1
Camidge, DR; Erickson, TM; Koeppe, JR; Miller, YE; Stuart, RW	1
Goto, Y; Hojo, M; Kobayashi, N; Kudo, K; Takeda, Y	1
Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N	1
Allen, CT; Chen, Z; Citrin, D; Colevas, AD; Dancey, J; Gius, D; Harold, NA; Morris, JC; Muir, C; Nottingham, L; Rudy, S; Singh, AK; Van Waes, C	1
Hammersley, JR; Kanjwal, S; Taj, A	1
Fukui, T; Hataishi, R; Igawa, S; Jiang, SX; Katagiri, M; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Otani, S	1
Abe, K; Akasaka, K; Imai, Y; Imura, J; Kaburagi, T; Nagao, K; Ohmori, K; Sagara, H; Ueda, Y; Yasuda, S	1
Chang, SC; Kuo, LC; Lin, PC; Wang, KF; Yuan, MK	1
Aoe, K; Bessho, A; Fujiwara, K; Harita, S; Hotta, K; Kamei, H; Kato, K; Kawai, H; Kiura, K; Kuyama, S; Maeda, T; Moritaka, T; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T; Yoshioka, H	1
Choi, PJ; Kim, KN; Lee, KN; Lee, SK; Roh, MS; Son, C; Um, SJ; Yang, DK	1
Liao, ML; Qin, SK; Sun, Y; Wu, YL; Zhou, CC	1
Fukuoka, M; Makimura, C; Nakagawa, K; Okamoto, I; Takeda, M	1
Chang, CY; Chang, SC; Chen, CY; Yu, CJ	1
Murashige, N; Oshima, Y; Tanimoto, T	1
Chang, YH; Lim, KH	1
Jones, SJ; Milenkova, T	1
Daum, S; Epple, HJ; Grozdanovic, Z; Kunkel, J; Loddenkemper, C; Schmittel, A; Schulze, K; Zeitz, M	1
Chang, HT; Chen, CA; Chen, CY; Chen, YJ; Chong, NS; Hsieh, CH; Hsieh, YP; Lin, SC; Lin, SL; Shueng, PW; Wang, LY	1
Grazioso Russi, E; Numico, G; Silvestris, N	1
Bar-Sela, G; Haim, N; Nasrallah, H	1
Asano, K; Bozec, A; Gresh, L; Ikeda, E; Kamiya, K; Kobayashi, K; Matsuo, K; Takada, Y; Toyama, Y; Wagner, EF; Watanabe, M	1
Dallas, JL; Jantz, MA; Kaye, FJ; Lightsey, JL; Sonntag, C	1
Dallas, J; Jantz, MA; Kaye, FJ	1
Chang, SC; Hsu, SY; Kuo, LC; Lai, JI; Lai, YC; Lin, PC; Wang, WS	1
Barratt, BJ; Fukuoka, M; Hada, S; Jawaid, A; Kamatani, N; Kato, H; Kudoh, S; March, R; Mushiroda, T; Nakamura, Y; Nakata, K; Nyberg, F; Ohe, Y; Takahashi, A; Umemura, T	1
Akimoto, S; Clausen, IG; Dobashi, T; Fukuoka, M; Harbron, CG; Higenbottam, T; Kato, H; Kawakami, T; Kihara, M; Komatsu, Y; Kudoh, S; Kyono, Y; Marko-Varga, G; Nagasaka, K; Nakata, K; Nishimura, T; Nyberg, F; Ogiwara, A; Ohe, Y; Otsuji, M; Peers, IS; South, MC; Takami, S; Tu, HK; Wada, K	1
Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Liu, YC; Tang, GJ; Wei, YF; Yu, CJ; Yuan, MK	1
Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Tachikawa, R; Tomii, K; Yoshioka, H	1
Azuma, A; Hoshino, T; Mizushima, T; Namba, T; Tanaka, K	1
Beijnen, JH; Lankheet, NA; Malingré, MM; Schaefer-Prokop, CM; Staaks, GH; ter Heine, R; van den Bosch, RT; van den Brand, JJ; van der Westerlaken, MM	1
Daw, HA; Peerzada, MM; Spiro, TP	1
Hamatani, Y; Kim, YH; Masago, K; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y	1
Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Kuo, LC; Lai, YC; Liu, YC; Yu, CJ; Yuan, MK	1
Ando, M; Fukuoka, M; Johkoh, T; Kudoh, S; Nakagawa, K; Ohe, Y; Seki, A; Takemoto, S; Yamazaki, N	1
Koma, Y; Matsuoka, H; Suzuki, Y; Yoshimatsu, H	1
Jin, C; Li, W; Li, Y; Ren, S; Zhang, D; Zhao, Z	1
Gao, G; Ren, S; Wu, X; Zhou, C	1
Matsuo, K; Takada, Y	1
Ebina, M; Gomi, K; Inoue, A; Kikuchi, T; Kimura, Y; Maemondo, M; Moriya, T; Nukiwa, T; Saijo, Y; Tokue, Y	1
Ouchi, Y; Teramoto, S; Yamamoto, H	1
Hanajiri, K; Maruyama, T; Mitsui, H; Nakajima, J; Omata, M	1
Genma, A; Kudo, S; Yoshimura, A	1
Konecny, GE; Slamon, DJ; Wilson, CA	1
Congleton, J; Harper-Wynne, C; O'Brien, M; Sumpter, K	1
Kodama, T; Kunitoh, H; Kusumoto, M; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Yamamoto, N; Yamamoto, S	1
Hirano, A; Kawata, N; Kimura, G; Okada, C; Shibayama, T; Soda, R; Tada, A; Takahashi, K; Takigawa, N; Yamadori, I	1
Camus, P; Ebina, M; Kudoh, S	1
Ben-Porat, L; Heelan, RT; Heinemann, MH; Kris, MG; Miller, VA; Pao, W; Pizzo, BM; Sachs, DL; Shah, NT; Tyson, LB	1
Choe, JK; Cogswell, J; Kasimis, B; Nagaria, NC	1
Chiu, CH; Perng, RP; Shih, YN; Tsai, CM	1
Hasegawa, Y; Imaizumi, K; Kataoka, K; Kawabe, T; Kimura, T; Kondoh, Y; Kume, H; Nishiyama, O; Shimokata, K; Taniguchi, H	1
Fukuoka, M; Ichinose, Y; Jiang, H; Kato, H; Nagai, K; Tada, H; Tsuboi, M; Tsuchiya, R; Wada, H	1
Hotta, K; Kanehiro, A; Kishino, D; Kiura, K; Nishii, K; Notohara, K; Tabata, M; Tanimoto, M; Tanimoto, Y; Ueoka, H; Umemura, S	1
Goto, K; Kakinuma, R; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K	1
Baldwin, PD; Lundberg, AS; Tammaro, KA	1
Eguchi, K; Koboyashi, T; Seki, N; Seto, T; Shioya, S; Tanigaki, T; Uematsu, K; Umemura, S	1
Abe, S; Harada, K; Inomata, S; Kanai, A; Kitajima, H; Saikai, T; Takahashi, H; Taniguchi, H	1
Endo, M; Johkoh, T; Kimura, K; Yamamoto, N	1
Cersosimo, RJ	1
Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K	1
Ando, M; Ariyoshi, Y; Fukuoka, M; Okamoto, I; Seto, T; Takeda, K; Tamura, K; Yamamoto, N	1
Sandler, AB	1
Kudoh, S; Yoshimura, A	1
Shiratori, M; Takahashi, H	1
Kudo, S	1
Chida, K; Miyazaki, K; Ogura, T; Sugiyama, Y; Yamaguchi, T	1
Itoh, Y; Oishi, R; Sendo, T	1
Iwanaga, K; Tohda, Y	1
Beckett, LA; Gandara, DR; Shelton, DK; Yoneda, KY	1
Kubota, K	1
Ishikawa, N	1
Brun, L; Colin, G; Copin, MC; Lafitte, JJ; Makris, D; Marquette, CH; Scherpereel, A	1
Fukui, T; Mitsudomi, T	2
Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C	1
Azzoli, CG; Ginsberg, MS; Kris, MG; Liu, V; Miller, VA; Travis, W; White, DA; Zakowski, MF	1
Fujita, S; Hoshino, Y; Ichikawa, M; Masago, K; Mio, T; Mishima, M; Nakamura, H; Nakamura, T; Sakuma, K; Tabata, C; Ueda, S; Yodoi, J	1
Armour, A; Fukuoka, M; Higenbottam, T; Ichinose, Y; Itoh, Y; Jiang, H; Kato, H; Kudoh, S; Nakagawa, K; Nakata, K; Nishiwaki, Y; Nyberg, F; Suga, M; Tsuboi, M; Watkins, C; Yokota, S	1
Asahina, H; Konishi, J; Nishimura, M; Suzuki, M; Yamazaki, K	1

Reviews

25 review(s) available for quinazolines and Lung Diseases, Interstitial

Article	Year
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). Japanese journal of clinical oncology, 2013, Volume: 43, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Quinazolines; Smoking	2013
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 83, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Risk; Survival Analysis	2014
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. Journal of chemotherapy (Florence, Italy), 2015, Volume: 27, Issue:1 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors	2015
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Future oncology (London, England), 2015, Volume: 11, Issue:7 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk	2015
Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review. Tumori, 2015, Jul-24, Volume: 101, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autopsy; Critical Care; Diagnosis, Differential; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed	2015
Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:1 Topics: Acute Disease; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Review Literature as Topic; Treatment Outcome	2011
Advances in EGFR-directed therapy in head and neck cancer. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis	2011
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung cancer (Amsterdam, Netherlands), 2012, Volume: 75, Issue:3 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Myocardial Infarction; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines	2012
Pulmonary toxicities of tyrosine kinase inhibitors. Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:11 Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines	2011
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature. Lung cancer (Amsterdam, Netherlands), 2012, Volume: 77, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2012
Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review. International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:10 Topics: Adenocarcinoma; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2012
[Non-small cell lung cancer: 2) Epidermal growth factor receptor inhibitor and severe adverse phenomena]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Jul-10, Volume: 92, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines	2003
Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention? Journal of the National Cancer Institute, 2003, Dec-17, Volume: 95, Issue:24 Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Protein-Tyrosine Kinases; Quinazolines	2003
Interstitial lung disease associated with drug therapy. British journal of cancer, 2004, Volume: 91 Suppl 2 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Respiratory Distress Syndrome; Risk Factors	2004
Gefitinib: an adverse effects profile. Expert opinion on drug safety, 2006, Volume: 5, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines	2006
Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:5 Suppl 2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines	2006
[Current status and problems of anticancer drug-induced lung injuries]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7 Topics: Antineoplastic Agents; Diagnosis, Differential; Gefitinib; Humans; Lung Diseases, Interstitial; Neoplasms; Product Surveillance, Postmarketing; Quinazolines; Risk Factors	2006
[Diffuse lung diseases and biological markers in serum]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Jun-10, Volume: 95, Issue:6 Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers; Collagen Diseases; Gefitinib; Humans; Lung Diseases, Interstitial; Mucin-1; Mucins; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Radiation Pneumonitis; Reagent Kits, Diagnostic; Respiratory Distress Syndrome; Sensitivity and Specificity	2006
[Drug induced lung injuries in Japanese population]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Jun-10, Volume: 95, Issue:6 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Asian People; Bleomycin; Gefitinib; Genetic Predisposition to Disease; Humans; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial; Pulmonary Alveoli; Quinazolines; Racial Groups	2006
[Drug-induced lung diseases]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2006, Volume: 127, Issue:6 Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antirheumatic Agents; Contrast Media; Drugs, Chinese Herbal; Gefitinib; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Iodine Radioisotopes; Lung Diseases, Interstitial; Minocycline; Paclitaxel; Quinazolines	2006
[Drug-induced lung injury]. Arerugi = [Allergy], 2007, Volume: 56, Issue:1 Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Diseases, Interstitial; Prognosis; Quinazolines; Thoracoscopy	2007
[What is drug-epidemiology?]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Jun-10, Volume: 96, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Quinazolines	2007
[Major drug-induced lung diseases: adverse effects of newly developed molecular targeted drugs]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Jun-10, Volume: 96, Issue:6 Topics: Antineoplastic Agents; Gefitinib; Gene Targeting; Humans; Lung Diseases, Interstitial; Quinazolines	2007
[Gefitinib and epidermal growth factor receptor gene mutation]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8 Topics: Adenocarcinoma; Antineoplastic Agents; Enzyme Inhibitors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Respiratory Distress Syndrome; Smoking	2007
Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. General thoracic and cardiovascular surgery, 2008, Volume: 56, Issue:3 Topics: Adenocarcinoma; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Incidence; Lung Diseases, Interstitial; Mutation; Protein Kinase Inhibitors; Quinazolines	2008

Trials

9 trial(s) available for quinazolines and Lung Diseases, Interstitial

Article	Year
Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661). Clinical lung cancer, 2013, Volume: 14, Issue:4 Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Tandem Mass Spectrometry	2013
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer science, 2014, Volume: 105, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Treatment Outcome	2014
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infections; Lung Diseases, Interstitial; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Paclitaxel; Pilot Projects; Quinazolines; Radiotherapy Dosage; Remission Induction; Stomatitis	2010
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:2 Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate	2010
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 45, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis	2004
Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anti-cancer drugs, 2005, Volume: 16, Issue:10 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Postoperative Period; Quinazolines	2005
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-01, Volume: 24, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed	2006
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2007
Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease. Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:23 Topics: Aged; Antineoplastic Agents; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Oxidative Stress; Quinazolines; Thioredoxins	2007

Other Studies

78 other study(ies) available for quinazolines and Lung Diseases, Interstitial

Article	Year
Acceleration of interstitial lung disease induced by raltitrexed. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:5 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Humans; Lung Diseases, Interstitial; Male; Quinazolines; Thiophenes	2020
Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2017, Volume: 58, Issue:2 Topics: Aged; Female; Humans; Lung Diseases, Interstitial; Platelet Aggregation Inhibitors; Pneumonia; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2017
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs. Clinical lung cancer, 2017, Volume: 18, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines	2017
[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2018, Volume: 138, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Afatinib; Bortezomib; Carbazoles; Cluster Analysis; Crizotinib; Dasatinib; Databases as Topic; Datasets as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Lung Diseases, Interstitial; Molecular Targeted Therapy; Particle Size; Piperidines; Pyrazoles; Pyridines; Quinazolines; Time Factors	2018
[Fatal interstitial lung disease associated with erlotinib use]. Nederlands tijdschrift voor geneeskunde, 2013, Volume: 157, Issue:7 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2013
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2013
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma. Journal of the Chinese Medical Association : JCMA, 2013, Volume: 76, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2013
Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia. Oncotarget, 2013, Volume: 4, Issue:4 Topics: Antibodies, Neutralizing; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; Interleukin-6; Lung Diseases, Interstitial; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tyrphostins; Up-Regulation	2013
Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study. Clinical lung cancer, 2014, Volume: 15, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Erlotinib Hydrochloride; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Tomography, X-Ray Computed	2014
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2014
Is the evidence of the Supreme Court Ruling of gefitinib litigation in Japan scientific? The International journal of risk & safety in medicine, 2014, Volume: 26, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Labeling; Drug Packaging; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines	2014
Interstitial lung disease arising from erlotinib treatment in a Caucasian patient. Clinical lung cancer, 2015, Volume: 16, Issue:2 Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; White People	2015
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. Cancer research and treatment, 2016, Volume: 48, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Retrospective Studies; Seoul	2016
[Interstitial lung disease induced by raltitrexed-oxaliplatin based chemotherapy for colorectal cancer: a case report]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2015, Mar-01, Volume: 39, Issue:2 Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Lung Diseases, Interstitial; Male; Organoplatinum Compounds; Oxaliplatin; Prednisone; Quinazolines; Thiophenes	2015
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells. PloS one, 2015, Volume: 10, Issue:8 Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclin D1; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-2; Gefitinib; Humans; Lung Diseases, Interstitial; Phosphorylation; Pulmonary Alveoli; Quinazolines; Signal Transduction; Taurochenodeoxycholic Acid	2015
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. Oncotarget, 2015, Dec-22, Volume: 6, Issue:41 Topics: Animals; Antineoplastic Agents; Bleomycin; Blotting, Western; Epithelial-Mesenchymal Transition; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Diseases, Interstitial; Male; Metformin; Pulmonary Fibrosis; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Transforming Growth Factor beta	2015
Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:2 Topics: Adrenal Cortex Hormones; Afatinib; Aged, 80 and over; Humans; Lung Diseases, Interstitial; Male; Quinazolines	2017
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. Clinical lung cancer, 2017, Volume: 18, Issue:1 Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment	2017
Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer. Respiratory investigation, 2016, Volume: 54, Issue:6 Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; ErbB Receptors; Female; Humans; Intra-Abdominal Fat; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Salvage Therapy; Survival Rate	2016
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Lung Diseases, Interstitial; Nitriles; Quinazolines; Triazoles	2016
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease. Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Prednisolone; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome	2017
From nihilism to individualism: the evolution of lung cancer therapy. American journal of respiratory and critical care medicine, 2008, Jun-15, Volume: 177, Issue:12 Topics: Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008
Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation. Cancer science, 2008, Volume: 99, Issue:8 Topics: Adenocarcinoma; Animals; Gefitinib; Gene Expression; Humans; In Vitro Techniques; Lipopolysaccharides; Lung Diseases, Interstitial; Mice; Pneumonia; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein A; Quinazolines; Signal Transduction	2008
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:9 Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed	2008
Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:11 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Chronic Disease; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Female; HIV; HIV Infections; Humans; Lung Diseases, Interstitial; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines	2008
Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report. Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Lung Neoplasms; Methylprednisolone; Muscular Diseases; Prednisolone; Quinazolines	2010
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:8 Topics: Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2009
Gefitinib: a second look. Non-small cell lung cancer: still very disappointing. Prescrire international, 2009, Volume: 18, Issue:102 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diarrhea; Docetaxel; Drug Approval; ErbB Receptors; France; Gefitinib; Humans; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Quinazolines; Skin Diseases; Taxoids	2009
New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung. American journal of therapeutics, 2011, Volume: 18, Issue:1 Topics: Aged; Biopsy; Brain Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Quinazolines; Tomography, X-Ray Computed	2011
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4 Topics: Adenocarcinoma; Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2010
Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA; Female; Gefitinib; Genotype; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Quinazolines	2010
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors	2010
Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis. The clinical respiratory journal, 2009, Volume: 3, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis	2009
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2010
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2010
Interstitial lung disease and gefitinib. The New England journal of medicine, 2010, 10-14, Volume: 363, Issue:16 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Product Surveillance, Postmarketing; Quinazolines	2010
Interstitial lung disease and gefitinib. The New England journal of medicine, 2010, 10-14, Volume: 363, Issue:16 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Quinazolines	2010
ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Prognosis; Quinazolines	2010
Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma. Pancreas, 2011, Volume: 40, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Pancreatic Neoplasms; Quinazolines	2011
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report. BMC cancer, 2010, Dec-31, Volume: 10 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dyspnea; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2010
Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines	2012
Interstitial lung disease induced by gefitinib and toll-like receptor ligands is mediated by Fra-1. Oncogene, 2011, Sep-08, Volume: 30, Issue:36 Topics: Animals; Chemokine CCL2; Female; Gefitinib; Humans; Ligands; Lipopolysaccharides; Lung Diseases, Interstitial; Macrophages, Alveolar; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Transgenic; Proto-Oncogene Proteins c-fos; Quinazolines; Toll-Like Receptors	2011
Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:6 Topics: Adenocarcinoma; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Retreatment; Treatment Outcome	2011
Erlotinib or gefitinib for non-small-cell lung cancer. The New England journal of medicine, 2011, 06-16, Volume: 364, Issue:24 Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2011
Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:7 Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Alanine Transaminase; Anti-Inflammatory Agents; Antineoplastic Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Function Tests; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Muscle Weakness; Quinazolines; Radiography, Thoracic	2011
Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data. Pharmacogenomics, 2011, Volume: 12, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Gefitinib; Genome-Wide Association Study; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Retrospective Studies	2011
Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients. PloS one, 2011, Volume: 6, Issue:7 Topics: Asian People; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Databases, Protein; Discriminant Analysis; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Peptides; Phenotype; Proteomics; Quality Control; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry	2011
Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease. International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Radiography, Thoracic; Retrospective Studies; Tomography, X-Ray Computed	2011
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Analysis	2011
Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis. PloS one, 2011, Volume: 6, Issue:11 Topics: Animals; Cell Line, Tumor; ErbB Receptors; Gefitinib; HSP70 Heat-Shock Proteins; Humans; Immunoblotting; Lung Diseases, Interstitial; Mice; Mice, Transgenic; MicroRNAs; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Real-Time Polymerase Chain Reaction	2011
Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer. Clinical lung cancer, 2013, Volume: 14, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Female; Gefitinib; Hospital Mortality; Humans; Hypoxia; Incidence; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Taiwan	2013
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:8 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Survival Rate; Young Adult	2012
Fatal asymmetric interstitial lung disease after erlotinib for lung cancer. Respiration; international review of thoracic diseases, 2012, Volume: 84, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2012
[Four cases of interstitial lung disease induced by erlotinib and a review of the literatures]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:8 Topics: Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed	2012
Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease. The Keio journal of medicine, 2012, Volume: 61, Issue:4 Topics: Animals; Antineoplastic Agents; Chemokine CCL2; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Lipopolysaccharides; Lung Diseases, Interstitial; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Tumor Necrosis Factor-alpha	2012
Severe acute interstitial pneumonia and gefitinib. Lancet (London, England), 2003, Jan-11, Volume: 361, Issue:9352 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines	2003
More haste, less speed. The Lancet. Oncology, 2003, Volume: 4, Issue:6 Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Approval; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Research Design; Treatment Failure; United States; United States Food and Drug Administration	2003
Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373 Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pulmonary Fibrosis; Quinazolines; Radiography	2003
Clinical efficacy and toxiciy of gefitinib in patients with lung cancer. Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373 Topics: Aged; Antineoplastic Agents; Ascites; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hepatitis C, Chronic; Humans; Hypoalbuminemia; Liver Cirrhosis; Lung Diseases, Interstitial; Lung Neoplasms; Male; Quinazolines	2003
Severe acute interstitial pnuemonia and gefitinib. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 43, Issue:3 Topics: Acute Disease; Adenocarcinoma; Antineoplastic Agents; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines	2004
[Interstitial pneumonia due to gefitinib followed in detail by high-resolution CT in a patient with adenocarcinoma of the lung]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2004, Volume: 42, Issue:6 Topics: Adenocarcinoma; Aged; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed	2004
Practical management of patients with non-small-cell lung cancer treated with gefitinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-01, Volume: 23, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Interactions; ErbB Receptors; Exanthema; Eye; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Patient Education as Topic; Quinazolines; Radiography	2005
Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis; Quinazolines	2005
Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer. Journal of the Chinese Medical Association : JCMA, 2005, Volume: 68, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Quinazolines; Radiography; Treatment Outcome	2005
Interstitial lung disease associated with gefitinib. Respiratory medicine, 2006, Volume: 100, Issue:4 Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Chemokine CXCL10; Chemokines, CC; Chemokines, CXC; Female; Gefitinib; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Quinazolines; Radiography; Respiratory Function Tests; Retrospective Studies	2006
Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer. Internal medicine (Tokyo, Japan), 2005, Volume: 44, Issue:9 Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Quinazolines	2005
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2005, Volume: 11, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed	2005
Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology (Carlton, Vic.), 2006, Volume: 11, Issue:1 Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Photomicrography; Quinazolines; Tomography, X-Ray Computed	2006
Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respirology (Carlton, Vic.), 2006, Volume: 11, Issue:2 Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers; Biopsy; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mucin-1; Mucins; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Tomography, X-Ray Computed	2006
Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 52, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diagnosis, Differential; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiography, Thoracic; Retrospective Studies; Tomography, X-Ray Computed	2006
Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Japanese journal of clinical oncology, 2006, Volume: 36, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; X-Ray Film	2006
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Treatment Outcome	2006
[Diagnosis of and therapy for diffuse lung diseases (discussion)]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Jun-10, Volume: 95, Issue:6 Topics: Alveolitis, Extrinsic Allergic; Biomarkers; Bronchiolitis; Gefitinib; Humans; Isoxazoles; Leflunomide; Lung Diseases, Interstitial; Quinazolines; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed	2006
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC cancer, 2007, Aug-05, Volume: 7 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinazolines; Tomography, X-Ray Computed	2007
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anti-cancer drugs, 2007, Volume: 18, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography	2007
Pulmonary toxicity associated with erlotinib. Chest, 2007, Volume: 132, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2007
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. American journal of respiratory and critical care medicine, 2008, Jun-15, Volume: 177, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Gefitinib; Humans; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors	2008
Recurrent gefitinib-induced interstitial lung disease. Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Tomography, X-Ray Computed	2008